Safe Use of Systemic Anti-Cancer Therapy: Best Practice Recommendations

The Weill Cornell Medicine-Qatar designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to Ministry of Public Health's Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias. 

Bibliography:

1.  Bonnabry P, Cingria L, Ackermann M, et al. (2006) Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process. International Journal for Quality in Health Care, 18(1):9-16.
2.  Gandhi TK, Bartel SB, Shulman LN, et al. (2005) Medication safety in the ambulatory chemotherapy setting. Cancer, 104(11):2477-83.
3.  Goldspiel BR, DeChristoforo R, Daniels CE. (2000) A continuous-improvement approach for reducing the number of chemotherapy-related medication errors. American Journal of Health-System Pharmacy, 57(4):S4-9.
4.  Institute for Safe Medication Practices. (2020) ISMP Targeted Medication Safety Best Practices for Hospitals. Available from: https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pd (accessed Jan 2021).
5. Institute for Safe Medication Practices and Institute for Safe Medication Practices Canada. (2012) ISMP International Medication Safety Self Assessment® for Oncology. Available from: https://mssa.ismp-canada.org/oncology (accessed Jan 2021).
6.  Institute of Medicine, Committee on Identifying and Preventing Medication Errors; Aspden P, Wolcott J, Bootman JL, Cronenwett LR (eds). (2007) Preventing medication errors: Quality Chasm Series. Washington: The National Academies Press.
7.  Kruk ME, Ling EJ, Bitton A, et al. (2017) Building resilient health systems: a proposal for a resilience index. BMJ, 357:j2323.
8.  Mort D, Lansdown M, Smith N, et al. (2008) For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy. London: National Confidential Enquiry into Patient Outcome and Death.
9.  Nightingale F. (1863) Notes on hospitals. London: Longman, Green, Longman, Roberts, and Green.
10.  Perrow C. (1999) Normal Accidents: Living With High-Risk Technologies. Princeton, NJ: Princeton University Press, Princeton Paperbacks.
11.  Porter R. (1999) The greatest benefit to mankind: A medical history of humanity. New York: W.W. Norton.
12.  Ranchon, F, Salles G, Späth H, et al. (2011) Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer, 11,478.
13.  Schwappach DL, Gehring K. (2015) Frequency of and predictors for withholding patient safety concerns among oncology staff: a survey study. European Journal of Cancer Care, 24(3):395-403.
14.  Ulas A, Silay K, Akinci S, et al. (2015) Medication Errors in Chemotherapy Preparation and Administration: a Survey Conducted among Oncology Nurses in Turkey. Asian Pacific Journal of Cancer Prevention, 16(5):1699-705.
15.  Vincent C. (2011) Patient safety. Chichester: John Wiley & Sons.